What is HC Wainwright’s Forecast for ATXS Q1 Earnings?

Astria Therapeutics, Inc. (NASDAQ:ATXS) – HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Astria Therapeutics in a report released on Tuesday, March 11th. HC Wainwright analyst J. Pantginis anticipates that the biotechnology company will earn ($0.50) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Astria Therapeutics’ current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Astria Therapeutics’ Q2 2025 earnings at ($0.50) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.02) EPS and FY2026 earnings at ($1.87) EPS.

Astria Therapeutics (NASDAQ:ATXS) last released its earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.01.

ATXS has been the topic of several other reports. Citizens Jmp upgraded Astria Therapeutics to a “strong-buy” rating in a research note on Friday, January 31st. JMP Securities began coverage on Astria Therapeutics in a research note on Friday, January 31st. They set an “outperform” rating and a $26.00 price objective on the stock. Finally, Wedbush restated an “outperform” rating and set a $28.00 price objective (up from $27.00) on shares of Astria Therapeutics in a research note on Wednesday. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $26.67.

Astria Therapeutics Price Performance

Shares of ATXS opened at $6.45 on Friday. The business’s fifty day moving average price is $7.19 and its 200 day moving average price is $9.57. Astria Therapeutics has a 12-month low of $5.73 and a 12-month high of $16.90. The stock has a market capitalization of $364.00 million, a PE ratio of -3.09 and a beta of 0.69.

Institutional Investors Weigh In On Astria Therapeutics

Large investors have recently added to or reduced their stakes in the stock. KLP Kapitalforvaltning AS acquired a new stake in Astria Therapeutics in the fourth quarter worth $41,000. Tower Research Capital LLC TRC increased its position in Astria Therapeutics by 109.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company’s stock worth $47,000 after buying an additional 2,766 shares during the period. BNP Paribas Financial Markets acquired a new stake in Astria Therapeutics in the fourth quarter worth $50,000. Virtus ETF Advisers LLC acquired a new stake in Astria Therapeutics in the fourth quarter worth $65,000. Finally, Teacher Retirement System of Texas acquired a new stake in Astria Therapeutics in the fourth quarter worth $91,000. 98.98% of the stock is owned by institutional investors and hedge funds.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.